Calcium ionophore-treated myeloid cells acquire many dendritic cell characteristics independent of prior differentiation state, transformation status, or sensitivity to biologic agents

被引:61
作者
Koski, GK
Schwartz, GN
Weng, DE
Gress, RE
Engels, FHC
Tsokos, M
Czerniecki, BJ
Cohen, PA
机构
[1] NCI, Med Branch, Pathol Lab, Bethesda, MD 20892 USA
[2] Univ Penn, Med Ctr, Dept Surg, Philadelphia, PA 19104 USA
关键词
D O I
10.1182/blood.V94.4.1359.416k25_1359_1371
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We previously reported that treatment of human peripheral blood monocytes or dendritic cells (DC) with calcium ionophore (CI) led to the rapid (18 hour) acquisition of many characteristics of mature DC, including CD83 expression. We therefore investigated whether less-mature myeloid cells were similarly susceptible to rapid CI activation. Although the promyelocytic leukemia line HL-60 was refractory to cytokine differentiation, CI treatment induced near-uniform overnight expression of CD83, CD80 (B7.1), and CD86 (87.2), as well as additional characteristics of mature DC. Several cytokines that alone had restricted impact on HL-50 could enhance CI-induced differentiation and resultant T-cell sensitizing capacity, In parallel studies, CD34(pos) cells cultured from normal donor bone marrow developed marked DC-like morphology after overnight treatment with either rhCD40L or CI, but only CI simultaneously induced upregulation of CD83, CD80, and CD86, This contrasted to peripheral blood monocytes, in which such upregulation could be induced with either CI or rhCD40L treatment. We conclude that normal and transformed myeloid cells at many stages of ontogeny possess the capacity to rapidly acquire many properties of mature DC in response to CI treatment. This apparent ability to respond to calcium mobilization, even when putative signal-transducing agents are inoperative, suggests strategies for implementing host antileukemic immune responses.
引用
收藏
页码:1359 / 1371
页数:13
相关论文
共 58 条
[1]  
BALL ED, 1984, J CLIN INVEST, V73, P1072, DOI 10.1172/JCI111292
[2]  
Cardoso AA, 1996, BLOOD, V88, P41
[3]   FUNCTIONAL CD40 ON B-LYMPHOCYTES AND DENDRITIC CELLS [J].
CAUX, C ;
BURDIN, N ;
GALIBERT, L ;
HERMANN, P ;
RENARD, N ;
SERVETDELPRAT, C ;
BANCHEREAU, J .
RESEARCH IN IMMUNOLOGY, 1994, 145 (03) :235-239
[4]   ACTIVATION OF HUMAN DENDRITIC CELLS THROUGH CD40 CROSS-LINKING [J].
CAUX, C ;
MASSACRIER, C ;
VANBERVLIET, B ;
DUBOIS, B ;
VANKOOTEN, C ;
DURAND, I ;
BANCHEREAU, J .
JOURNAL OF EXPERIMENTAL MEDICINE, 1994, 180 (04) :1263-1272
[5]   GM-CSF AND TNF-ALPHA COOPERATE IN THE GENERATION OF DENDRITIC LANGERHANS CELLS [J].
CAUX, C ;
DEZUTTERDAMBUYANT, C ;
SCHMITT, D ;
BANCHEREAU, J .
NATURE, 1992, 360 (6401) :258-261
[6]   Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia [J].
Choudhury, A ;
Gajewski, JL ;
Liang, JC ;
Popat, U ;
Claxton, DF ;
Kliche, KO ;
Andreeff, M ;
Champlin, RE .
BLOOD, 1997, 89 (04) :1133-1142
[7]   CONTINUOUS GROWTH AND DIFFERENTIATION OF HUMAN MYELOID LEUKEMIC-CELLS IN SUSPENSION CULTURE [J].
COLLINS, SJ ;
GALLO, RC ;
GALLAGHER, RE .
NATURE, 1977, 270 (5635) :347-349
[8]   TERMINAL DIFFERENTIATION OF HUMAN PROMYELOCYTIC LEUKEMIA-CELLS INDUCED BY DIMETHYL-SULFOXIDE AND OTHER POLAR COMPOUNDS [J].
COLLINS, SJ ;
RUSCETTI, FW ;
GALLAGHER, RE ;
GALLO, RC .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1978, 75 (05) :2458-2462
[9]  
COLLINS SJ, 1987, BLOOD, V70, P1233
[10]  
Czerniecki BJ, 1997, J IMMUNOL, V159, P3823